Abstract
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
Competing Interest Statement
AW and MOAS have shares or options in UNION therapeutics. All other authors have no competing interests to declare.
Footnotes
↵* Shared last authorship: Xavier de Lamballerie (xavier.de-lamballerie{at}univ-amu.fr) and Morten Otto Alexander (morten.sommer{at}uniontherapeutics.com and msom{at}biosustain.dtu.dk)